Satellos Bioscience (MSLE) Other Non-Current Liabilities (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Other Non-Current Liabilities of $19.3 million for Q1 2026, up 24.84% quarter-over-quarter from $15.5 million in Q4 2025.
Satellos Bioscience (MSLE) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Other Non-Current Liabilities for 2 consecutive years, with $19.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $19.3 million; the TTM figure through Mar 2026 stood at $19.3 million (changed N/A YoY), while the FY2025 annual figure was $15.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $19.3 million in Q1 2026 per MSLE's latest filing, from $15.5 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $19.3 million in Q1 2026 and bottomed at $15.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Satellos Bioscience | 206.75 Mn | 206.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.33 Mn |
| Dec 31, 2025 | 15.48 Mn |